Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

F 11356, a Novel 5-Hydroxytryptamine (5-HT) Derivative with Potent, Selective, and Unique High Intrinsic Activity at 5-HT1B/1D Receptors in Models Relevant to Migraine

Gareth W. John, Petrus J. Pauwels, Michel Perez, Serge Halazy, Bruno Le Grand, Yvan Verscheure, Jean-Pierre Valentin, Christiane Palmier, Thierry Wurch, Philippe Chopin, Marc Marien, Mark S. Kleven, Wouter Koek, Marie-Bernadette Assié, Elisabeth Carilla-Durand, Jean-Pierre Tarayre and Francis C. Colpaert
Journal of Pharmacology and Experimental Therapeutics July 1999, 290 (1) 83-95;
Gareth W. John
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petrus J. Pauwels
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Perez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serge Halazy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Le Grand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yvan Verscheure
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Valentin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Palmier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thierry Wurch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Chopin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Marien
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark S. Kleven
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wouter Koek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Bernadette Assié
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Carilla-Durand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Tarayre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francis C. Colpaert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

F 11356 (4-[4-[2-(2-aminoethyl)-1H-indol-5-yloxyl]acetyl]piperazinyl-1-yl]benzonitrile) was designed to take advantage of the superior potency and efficacy characteristics of 5-hydroxytryptamine (5-HT) compared with tryptamine at 5-HT1B/1D receptors. F 11356 has subnanomolar affinity for cloned human and nonhuman 5-HT1B and 5-HT1Dreceptors, and its affinity for 5-HT1A and other 5-HT receptors, including the 5-ht1F subtype, is 50-fold lower and micromolar, respectively. In C6 cells expressing human 5-HT1B or human 5-HT1D receptors, F 11356 was the most potent compound in inhibiting forskolin-induced cyclic AMP formation (pD2 = 8.9 and 9.6), and in contrast to tryptamine and derivatives, it produced maximal enhancement of [35S]guanosine-5′-O-(3-thio)triphosphate-specific binding equivalent to 5-HT. F 11356 was equipotent to 5-HT (pD2 = 7.1 versus 7.2) and more potent than tryptamine derivatives in contracting rabbit isolated saphenous vein. In isolated guinea pig trigeminal ganglion neurons, F 11356 was more potent (pD2 = 7.3 versus 6.7) and induced greater increases in outward hyperpolarizing Ca2+-dependent K+current than sumatriptan. In anesthetized pigs, F 11356 elicited highly cranioselective, more potent (from 0.16 μg/kg i.v.) and greater carotid vasoconstriction than tryptamine derivatives. Decreases in carotid blood flow were observed in conscious dogs from 0.63 mg/kg oral F 11356 in the absence of changes in heart rate or behavior. Oral activity was confirmed when hypothermic responses were elicited in guinea pigs (ED50 = 1.6 mg/kg), suggesting that F 11356 also accesses the brain. F 11356 thus is a selective, high-potency agonist at 5-HT1B/1D receptors, which distinguishes itself from tryptamine and derivatives in exerting high intrinsic activity at these receptors in vascular and neuronal models relevant to migraine.

Footnotes

  • Send reprint requests to: Dr. G. W. John, Centre de Recherche Pierre FABRE, 17 Ave. Jean Moulin, 81106 Castres Cedex, France. E-mail: gareth.john{at}pierre-fabre.com

  • ↵1 Part of this work was presented at the IUPHAR meeting held in München, Germany, July 1998, and has been published in abstract form (John et al., 1998a, b; Pauwels et al., 1998a).

  • Abbreviations:
    5-HT
    5-hydroxytryptamine (serotonin)
    DHE
    dihydroergotamine
    F 11356
    4-[4-[2-(2-aminoethyl)-1H-indol-5-yloxyl]acetyl]piperazinyl-1-yl]benzonitrile HCl
    GTPγS
    guanosine-5′-O-(3-thio)triphosphate
    GR 127935
    2′-methyl-4′-(5-methyl[1,2,4]oxadiozol-3-yl)biphenyl-4-carboxylic acid[4-methoxy-3-(4-methyl piperazin-1-yl)phenyl]amide 2 HCl
    cAMP
    cyclic AMP
    l-NAME
    Nω-nitro-l-arginine methyl ester
    U 46619
    9,11-dideoxy-9α,11α-methanoepoxy PGF2α
    • Received December 14, 1998.
    • Accepted March 4, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 290 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 290, Issue 1
1 Jul 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
F 11356, a Novel 5-Hydroxytryptamine (5-HT) Derivative with Potent, Selective, and Unique High Intrinsic Activity at 5-HT1B/1D Receptors in Models Relevant to Migraine
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

F 11356, a Novel 5-Hydroxytryptamine (5-HT) Derivative with Potent, Selective, and Unique High Intrinsic Activity at 5-HT1B/1D Receptors in Models Relevant to Migraine

Gareth W. John, Petrus J. Pauwels, Michel Perez, Serge Halazy, Bruno Le Grand, Yvan Verscheure, Jean-Pierre Valentin, Christiane Palmier, Thierry Wurch, Philippe Chopin, Marc Marien, Mark S. Kleven, Wouter Koek, Marie-Bernadette Assié, Elisabeth Carilla-Durand, Jean-Pierre Tarayre and Francis C. Colpaert
Journal of Pharmacology and Experimental Therapeutics July 1, 1999, 290 (1) 83-95;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

F 11356, a Novel 5-Hydroxytryptamine (5-HT) Derivative with Potent, Selective, and Unique High Intrinsic Activity at 5-HT1B/1D Receptors in Models Relevant to Migraine

Gareth W. John, Petrus J. Pauwels, Michel Perez, Serge Halazy, Bruno Le Grand, Yvan Verscheure, Jean-Pierre Valentin, Christiane Palmier, Thierry Wurch, Philippe Chopin, Marc Marien, Mark S. Kleven, Wouter Koek, Marie-Bernadette Assié, Elisabeth Carilla-Durand, Jean-Pierre Tarayre and Francis C. Colpaert
Journal of Pharmacology and Experimental Therapeutics July 1, 1999, 290 (1) 83-95;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Antinociceptive Properties of Fenfluramine, a Serotonin Reuptake Inhibitor, in a Rat Model of Neuropathy
  • Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by 4-Aminoquinolines and Other Weak Bases: Mechanistic Studies
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics